[WIRB - IAA] Gilteritinib Monotherapy or in Combination with Decitabine in Elderly Untreated FLT3 mutated Acute Myeloid Leukemia With High and Low Variant Allele Frequency (VAF)
The purpose of this study is to determine the safety and acceptability of the experimental drug, gilteritinib, alone and with Decitabine.
Acute Myeloid Leukemia (AML)
-Participating in the Beat AML umbrella study master protocol (reference IRB# 16475)
-Newly diagnosed with AML
-Age 60 years or older at time of diagnosis
-Genetic marker (FLT3 mutation)
60 - n/a
Healthy Volunteers Needed
Duration of Participation
Study participation may include up to 5 years of study drug treatment. You will be followed for lifetime for survival, relapse and other outcomes.
Clinical Trials Information Line
Beat AML, LLC, a division of the Leukemia and Lymphoma Society, Inc
Supported by: Astellas Pharma Global Development, Inc. (APGD)